Substack Post | The Best Drug Isn't Always the Most Powerful One

The slide that wins over a pitch room is usually the one with the steepest dose-response curve — and Leen Kawas has come to see that as one of biotech's most persistent self-deceptions. This post walks through the FDA's Project Optimus reforms, the cabazitaxel trial that proved a lower dose saved lives without losing efficacy, and why the dose a patient can sustain for years matters more than the one that looks best on a 12-week chart.

Read the Full Post Here